Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856716 | 0.86 | PIK3CA (0.48) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4067340 | 0.83 | PIK3CA (0.46) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1862201 | 0.80 | PIK3CA (0.67) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1857827 | 0.79 | PIK3CA (0.42) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4438133 | 0.78 | PIK3CA (0.54) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL189671 | 0.78 | PIK3CA (0.54) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL190049 | 0.77 | PIK3CA (0.44) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1859279 | 0.77 | PIK3CA (0.53) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1088710 | 0.76 | PIK3CD (0.71) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL1181831 | 0.76 | PIK3CA (0.43) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2046799-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Genentech, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | PIK3CA 6/4885MTOR 86/4885PIK3CD 10/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | PIK3CA 1/4885MTOR 43/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.